• head_banner_01

Industry news

  • Tadalafil Application

    Tadalafil Application

    Tadalafil is a medication used to treat erectile dysfunction and certain symptoms of an enlarged prostate. It works by improving blood flow to the penis, enabling a man to achieve and maintain an erection. Tadalafil belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors, ...
    Read more
  • New Products Alert

    New Products Alert

    In order to provide more options to the clients in Cosmetic peptides industry, Gentolex will constantly add new products to the list. High quality with varieties categories, there are totally four different series defined by functions in protecting skins, including Anti-aging & anti-wrinkle, ...
    Read more
  • Acadia Trofinetide Phase III Clinical Top-Line Results Positive

    Acadia Trofinetide Phase III Clinical Top-Line Results Positive

    On 2021-12-06, US time, Acadia Pharmaceuticals (Nasdaq: ACAD) announced the positive top-line results of its Phase III clinical trial of its drug candidate, Trofinetide. The phase III trial, called Lavender, is mainly used to evaluate the safety and efficacy of Trofinetide in the treatment of Ret...
    Read more
  • The research progress of opioid peptides from the approval of Difelikefalin

    The research progress of opioid peptides from the approval of Difelikefalin

    As early as 2021-08-24, Cara Therapeutics and its business partner Vifor Pharma announced that its first-in-class kappa opioid receptor agonist difelikefalin (KORSUVA™) was approved by the FDA for the treatment of chronic kidney disease (CKD) patients (positive Moderate/severe pruritus with hemod...
    Read more
  • RhoVac Cancer Peptide Vaccine RV001 to be Patented by the Canadian Intellectual Property Office

    RhoVac Cancer Peptide Vaccine RV001 to be Patented by the Canadian Intellectual Property Office

    Canada time 2022-01-24, RhoVac, a pharmaceutical company focused on tumor immunology, announced that its patent application (No. 2710061) for its cancer peptide vaccine RV001 will be authorized by the Canadian Intellectual Property Office (CIPO). Previously, the company has obtained patents relat...
    Read more